MedPath

Randomized Controlled Trials on Laparoscopic No. 14v LNS Dissection

Not Applicable
Conditions
Stomach Neoplasms
Interventions
Procedure: D2 lymphadenectomy including No. 14v
Procedure: lymphadenectomy excluding No. 14v
Registration Number
NCT02789891
Lead Sponsor
Fujian Medical University
Brief Summary

The purpose of this study is to explore the short-term, long-term and oncological outcomes of laparoscopic No. 14v lymph node dissection in advanced lower third gastric cancer.

Detailed Description

A prospective randomized comparison of laparoscopic No. 14v lymph node dissection in advanced lower third gastric cancer will be performed, to evaluate the short-term, long-term and oncological outcomes. The evaluation parameters are perioperative clinical efficacy, postoperative life quality, immune function and 3-year survival and recurrence rates.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
326
Inclusion Criteria

• Age from 18 to 75 years

  • Primary lower third gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy
  • cT2-4a, N0-3, M0 at preoperative evaluation according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual Seventh Edition
  • No distant metastasis is observed. And the spleen, pancreas or other adjacent organs are not involved by the tumor.
  • Performance status of 0 or 1 on Eastern Cooperative Oncology Group scale (ECOG)
  • American Society of Anesthesiology score (ASA) class I, II, or III
  • Written informed consent
Exclusion Criteria

• Women during pregnancy or breast-feeding

  • Severe mental disorder
  • History of previous upper abdominal surgery (except laparoscopic cholecystectomy)
  • History of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal dissection
  • Enlarged or bulky regional lymph node envelop important vessels
  • History of other malignant disease within past five years
  • History of previous neoadjuvant chemotherapy or radiotherapy
  • History of unstable angina or myocardial infarction within past six months
  • History of cerebrovascular accident within past six months
  • History of continuous systematic administration of corticosteroids within one month
  • Requirement of simultaneous surgery for other disease
  • Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer
  • FEV1<50% of predicted values

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
D2 Lymphadenectomy including No. 14vD2 lymphadenectomy including No. 14vLaparoscopic distal gastrectomy with D2 lymphadenectomy including No. 14v lymph node dissection will be performed for the treatment of patients assigned to this group
D2 lymphadenectomy excluding No. 14vlymphadenectomy excluding No. 14vLaparoscopic distal gastrectomy with D2 lymphadenectomy excluding No. 14v lymph node dissection will be performed for the treatment of patients assigned to this group
Primary Outcome Measures
NameTimeMethod
3-year disease overall survival rate36 months
Secondary Outcome Measures
NameTimeMethod
No.14v Lymph node metastasis rate10 days
The results of endoscopy12 months

the results of endoscopy on postoperative 3 and 12 months

Time to soft diet10 days
The variation of cholesterol12 months

The variation of cholesterol on postoperative 3, 6, 9 and 12 months

3-year free survival rate36 months
The variation of weight12 months

The variation of weight on postoperative 3, 6, 9 and 12 months

Time to first liquid diet10 days
Morbidity and mortality30 days; 36 months

The early postoperative complication and mortality are defined as the event observed within 30 days after surgery, while the time frame for late complication is the period from postoperative day 31th to the end of month 36th.

3-year recurrence pattern36 months

Recurrence patterns are classified into five categories at the time of first diagnosis: locoregional, hematogenous, peritoneal, distant lymph node, and mixed type

Duration of hospital stay10 days
The variation of albumin12 months

The variation of albumin on postoperative 3, 6, 9 and 12 months

The values of white blood cell count7 days

the values of white blood cell count from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded

The values of hemoglobin7 days

and the values of hemoglobin from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded.

Time to first ambulation10 days

The data of postoperative recovery course.

The number of lymph node dissection10day
The daily highest body temperature7 day

The daily highest body temperature before discharge

Time to first flatus10 days
The amount of abdominal drainage10 days
Intraoperative lymph node dissection time1 day

intraoperative No.14v lymph node dissection time includes infrapyloric area lymph node,suprapancreatic area lymph node,splenic hilar area lymph node, cardial area lymph node

The amount of use of titanium clip1 day
The rate of conversion to laparotomy1 day
Visual Analog Score for pain7 days

the values of visual analog score for pain before operation and on postoperative day 1 to day 7 are recorded.

EORTC QLQ-C30 and QLQ - STO22Time Frame: 36 months

European Organization fo Research and Treatment(EORTC) QLQ-C30 and QLQ - STO22 before operation and on postoperative month 6,12,36 are recorded.

Blood transfusion10 days
The number of positive lymph nodes1 day
Intraoperative blood loss1 day
Intraoperative injury1 day
The values of C-reactive protein7 days

and the values of C-reactive protein from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded.

The values of relevant immune cytokines7 days

and the values of relevant immune cytokines including T cell percentage, T-helper lymphocytes (CD4+) percentage, T-suppressor lymphocytes (CD8+) percentage, natural killer (NK) cells percentage from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded.

The values of prealbumin7 days

and the values of prealbumin from peripheral blood before operation and on postoperative day 1, 3, 5 are recorded.

© Copyright 2025. All Rights Reserved by MedPath